Treatment effect of intravenous high-dose selenium in sepsis phenotypes: a retrospective analysis of a large multicenter randomized controlled trial
Authors' conclusion
Application of the four sepsis phenotypes to the SISPCT study cohort showed discrete but non-significant mortality differences within 28 days. However, beneficial treatment effects of high-dose intravenous selenium were still not detectable after categorizing the SISPCT study cohort according to four phenotype criteria.
Study context
- Population
- Patients with sepsis or septic shock in the SISPCT trial, assigned to four phenotypes by comparison with the Sepsis Endotyping in Emergency Care (SENECA) validation cohort
- Participants
- 1,089 patients
- Comparison
- High-dose IV selenium vs placebo across sepsis phenotypes
Methodological detailsplacebo-controlled, multicentre, retrospective, Survival analyses by Kaplan-Meier and log-rank tests
- Placebo-controlled
- Multicentre
- Retrospective
- Survival analyses by Kaplan-Meier and log-rank tests
Primary result
As reported in the abstract
Effect of selenium on mortality and other outcomes by sepsis phenotype (subgroup)
- No robust effect of selenium on mortality and other outcomes in any sepsis phenotype
Further findings
Phenotype frequencies
- α
- 2.2%
- β
- 6.3%
- γ
- 68.0%
- δ
- 23.4%
- Markedly different from previous reports
Mortality by phenotype · 28 days
- α-phenotype
- 20.8%
- β-phenotype
- 20.3%
- γ-phenotype
- 27.1%
- δ-phenotype
- 28.5%
- Differences between phenotypes not significant overall
Original publication
Treatment effect of intravenous high-dose selenium in sepsis phenotypes: a retrospective analysis of a large multicenter randomized controlled trial. J Intensive Care. Published 14 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →